Japan Conjugate Vaccine Market (2018-2023)

June 2018 | 70 pages | ID: J98D47B2110EN
Netscribes (India) Pvt. Ltd.

Abstracts

The report is sent in 5-10 business days after order is placed.

Japan Conjugate Vaccine Market:

Conjugate Vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protects against invasive diseases. Japan is one of the most prominent markets of conjugate vaccines.

Japan, at 84 years, has one of the highest life expectancies in the world. Currently, both PPSV–23 and PCV–13 are available for the elderly for the prevention of Streptococcus pneumoniae -related diseases. Despite these two vaccines being made available for the elderly, the national immunization program launched for these aged 65 and older as on October 1, 2014, only subsidized PPSV–23. Japan has frequently reported low incidence of Meningococcal disease, and therefore the disease is not considered a high health care priority.

Market Segmentation:

Based on disease indication, the market is segmented into:

• Pneumococcal
• Haemophilus influenza type b
• Diphtheria-tetanus-pertussis
• Meningococcal
• Others

Based on end user, the market is segmented into:

• Paediatric
• Adult

Key growth factors:

Japan is projected to be a stable market for conjugate vaccines during the forecast period. Rapidly increasing geriatric population, rise in consumer awareness, growing disposable income and healthcare expenditure and modernization of healthcare infrastructure will drive the Japan market for conjugate vaccines. Japan, with the highest life expectancy out of all other countries in the world, has its old population creating demand for adult conjugate vaccines.

Threats and key players:

1. Although the health situation in Japan is among the best in the world, there is still a significant gap to be filled, with regard to the use of vaccines to prevent severe infections. This gap has major implications for public health, both in Japan and other countries since Japan is cited as a source for infectious diseases to countries that have those diseases under better control through vaccination. There is also a need to organize an efficient immunization program, due to the limited resources for health care. Under-reporting, lack of awareness and focus on meningococcal disease are some of the major threats.

2. Major conjugate vaccine providers are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

What’s covered in the report?

1. Overview of the Japan conjugate vaccine market
2. Market drivers and challenges in the Japan conjugate vaccine market
3. Market trends in the Japan conjugate vaccine market
4. Historical, current and forecasted market size data for Japan based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for Japan based on end user (paediatric and adult conjugate vaccines) – by revenue and by volume
6. Analysis of the competitive landscape and profiles of major companies operating in the Japan market

Why buy?

• Understand the demand for conjugate vaccines to determine the viability of the market
• Develop strategies based on the drivers and trends for each of the segments
• Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
• Recognize the key competitors of this market and respond accordingly
• Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
• Define the competitive positioning by comparing the products and services with the key players in the market

Customizations available
With the given market data, Netscribes offers customizations according to specific needs.

Contents

CHAPTER 1: EXECUTIVE SUMMARY

1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary  I
1.4 Executive summary  II

CHAPTER 2: MARKET OVERVIEW

2.1. Market definitions
2.2. Japan market overview – by revenue
  Japan historical (2015-2017) market revenue (USD Bn)
  Japan forecasted (2018-2023) market revenue (USD Bn)
2.3. Japan market overview – by volume
  Japan historical (2015-2017) market volume (Million units)
  Japan forecasted (2018-2023) market volume (Million units)
2.4. Japan market drivers and challenges
  2.4.1. Japan market drivers
  2.4.2. Japan market challenges
2.5. Japan market trends
2.6. Value chain

CHAPTER 3: JAPAN MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION

3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): Pneumococcal – Japan (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Hib – Japan (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): DTP – Japan (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Meningococcal – Japan (USD Bn, Million units)

CHAPTER 4: JAPAN MAJOR SEGMENT OVERVIEW BY END USER

4.1. End-user: Pediatric, Adult by revenue, by volume, CAGR
  Overview by end user
  Market share (2015, 2018 & 2023): Paediatric – Japan (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Adult – Japan (USD Bn, Million units)

CHAPTER 5: COMPETITIVE LANDSCAPE

5.1. Company market share
  Top 5 companies
5.2. Company overview GlaxoSmithKline
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.2(A) Executive profile – GlaxoSmithKline
5.3. Company overview – Pfizer Inc.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.3(A) Executive profile  Pfizer Inc.
5.4. Company overview – Merck & Co.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.4(A) Executive profile  Merck & Co.
5.5. Company overview – Novartis
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.5(A) Executive profile  Novartis
5.6. Company overview – Sanofi Pasteur
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.6(A) Executive profile  Sanofi Pasteur
5.7. Company overview – CSL Limited
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.7(A) Executive profile  CSL Limited
Appendix
  List of tables
  Assumptions
  Conclusion
  Research methodology
  About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research